Finance

Lists
Q2 2026 earnings • released • EPS beat +61.90% • Revenue beat +107.37%
See results
ASMB:NASDAQ
Assembly Biosciences Inc
$31.06
-5.74%
(-1.89) 1D
Aug 17, 12:39:54 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ASMB...
Open
$32.57
High
$33.33
Low
$31.05
Mkt. cap
632.40M
Avg. vol.
176.93K
Volume
158.37K
52-wk high
$39.70
52-wk low
$20.23
EPS
-$1.29
Beta
1.10
Shares outstanding
20.36M
No. of employees
73
Open
$32.57
High
$33.33
Low
$31.05
Mkt. cap
632.40M
Avg. vol.
176.93K
Volume
158.37K
52-wk high
$39.70
52-wk low
$20.23
EPS
-$1.29
Beta
1.10
Shares outstanding
20.36M
No. of employees
73
News stories
From web sources and news partners
About Assembly Biosciences Inc
CEO-
Employees73
Founded2005
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteassemblybio.com
Analyst ratings
Based on 3 analysts giving stock ratings to ASMB in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ASMB in the last 3 months.
Highest
Current $31.06
$50.00 (+60.98%)
Average
$46.00 (+48.10%)
Lowest
$43.00 (+38.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Vamil Divan
Guggenheim
Buy
Reiterated
$43.00
+38.4%
08/16/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$45.00
+44.9%
06/12/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$45.00
+44.9%
06/12/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$50.00
+61%
06/03/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.20 / -$0.52
+61.90%beat
Revenue / Est. (USD)
13.37M / 6.45M
+107.37%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
10.79M
42.47M
8.21M
13.37M
Cost of goods sold
16.59M
17.25M
14.90M
14.92M
Cost of revenue
16.59M
17.25M
14.90M
14.92M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.08M
5.42M
4.68M
4.80M
Operating expense
5.08M
5.42M
4.68M
4.80M
Total operating expenses
21.67M
22.67M
19.58M
19.72M
Operating income
-10.88M
19.80M
-11.37M
-6.34M
Other non operating income
-
-
-
-
EBT including unusual items
-9.20M
22.09M
-9.08M
-3.86M
EBT excluding unusual items
-9.20M
22.09M
-9.08M
-3.86M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.20M
22.09M
-9.08M
-3.86M
Net profit margin
-85.23%
52.01%
-110.54%
-28.84%
Earnings per share
-0.72
2.48
-0.54
-0.20
Interest and investment income
1.69M
2.29M
2.29M
2.49M
Interest expense
-
-
-
-
Net interest expenses
1.69M
2.29M
2.29M
2.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.85M
19.83M
-11.34M
-6.32M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps